Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Top 4 Wholesalers on Solid Note with 30% Operating Profit Rise in FY2022
May 19, 2023
- Taiho Seals Trial Pact for Arcus Oncology Meds to Work with Gilead
May 19, 2023
- Qol to Further Expand Espha's AG Biz, Eyes Biosame Territory: Exec
May 19, 2023
- BMS Files Luspatercept for MDS Associated Anemia in Japan
May 19, 2023
- Lecanemab’s Social Value in Japan Simulated at 4.7 Million Yen per Patient/Year: Eisai
May 18, 2023
- Xocova Makes Up 11% of COVID Oral Drug Prescriptions Filled Outside Pharmacies
May 18, 2023
- Santen Set to Thwart Post-Launch Challenges Expected for Myopia Drug Hopefuls: President
May 18, 2023
- Takeda’s cTTP Therapy Gets Priority Review in US
May 18, 2023
- Lecanemab Accepted for Review by Canadian Authorities: Eisai/Biogen
May 18, 2023
- Sony, Astellas Ink Research Deal for ADC Discovery Using Linker Technology
May 17, 2023
- Nonprescription Obesity Med Unlikely to Hit Japan Market Until Next Year
May 17, 2023
- Daiichi Sankyo Set to Sharpen Focus on Innovation with Generic Divestment
May 17, 2023
- Kenzo Sawai to Quit Group Management to Focus on Advocacy
May 16, 2023
- Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
May 16, 2023
- Sumitomo Incurs 77 Billion Yen Operating Loss in FY2022 on Kynmobi Impairment Charge
May 16, 2023
- 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
May 16, 2023
- Eisai’s FY2022 Sales Slip 1.6% on Lower Milestones, Year-Before Gain
May 16, 2023
- FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
May 16, 2023
- Keytruda-Chemo Combo Filed for 1st Line Gastric Cancer in Japan: MSD
May 15, 2023
- Mitsubishi Tanabe Logs 38% Growth in Full-Year Sales, Returns to Profitability on Gilenya Royalties
May 15, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…